Summit Therapeutics Breakthrough: Phase III Trial Reveals Major Lung Cancer Treatment Success with 48% Risk Reduction

Akeso Announces First Patient Dosed in Phase III Trial of Ivonescimab as Consolidation Therapy for Limited-Stage SCLC After Definitive Radiotherapy

HONG KONG, Aug. 10, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its multicenter, randomized, double-blind Phase III study (AK112-311/HARMONi-9), evaluating ivonescimab, a first-in-class PD-1/VEGF bispecific antibody developed by…

Summit Therapeutics Breakthrough: Phase III Trial Reveals Major Lung Cancer Treatment Success with 48% Risk Reduction

New Phase III data shows ivonescimab significantly improved progression-free survival in NSCLC patients. See detailed trial results and Q2 financial highlights.